Ethanol induction of CYP2A5: Role of CYP2E1-ROS-Nrf2 pathway

Toxicological Sciences

Volumn 128, Issue 2, 2012, Pages 427-438

  Lu, Yongke ^a   Zhang, Xu Hannah ^a   Cederbaum, Arthur I ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Antioxidant.; CYP2A5; CYP2E1; Ethanol; Nrf2; ROS

Indexed keywords

ALCOHOL; CYTOCHROME P450 2A5; CYTOCHROME P450 2E1; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2;

ALCOHOL CONSUMPTION; ALCOHOL OXIDATION; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INDUCTION; FATTY LIVER; LIVER CELL; LIVER MICROSOME; LIVER PROTECTION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN FUNCTION; UPREGULATION;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2E1; ENZYME INDUCTION; ETHANOL; MICE; MICE, KNOCKOUT; MICROSOMES, LIVER; NF-E2-RELATED FACTOR 2; REACTIVE OXYGEN SPECIES;

EID: 84865375616     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfs164     Document Type: Article

References (46)

1. Abu-Bakar, A., Arthur, D. M., Aganovic, S., Ng, J. C., and Lang, M. A. (2011). Inducible bilirubin oxidase: A novel function for the mouse cytochrome P450 2A5. Toxicol. Appl. Pharmacol. 257, 14-22.
2. Abu-Bakar, A., Lamsa, V., Arpainen, S., Moore, M. R., Lang, M. A., and Hakkola, J. (2007). Regulation of CYP2A5 gene by the transcription factor nuclear factor (erythroid-derived 2)-like 2. Drug Metab. Disp. 35, 787-794.
3. Abu-Bakar, A., Moore, M. R., and Lang, M. A. (2005). Evidence for induced microsomal bilirubin degradation by cytochrome P450 2A5. Biochem. Pharmacol. 70, 1527-1535.
4. Abu-Bakar, A., Satarug, S., Marks, G. C., Lang, M. A., and Moore, M. R. (2004). Acute cadmium chloride administration induces hepatic and renal CYP2A5 mRNA, protein and activity in the mouse: Involvement of transcription factor NRF2. Toxicol. Lett. 148, 199-210.
5. Arpiainen, S., Järvenpää, S. M., Manninen, A., Viitala, P., Lang, M. A., Pelkonen, O., and Hakkola, J. (2008). Coactivator PGC-1alpha regulates the fasting inducible xenobiotic-metabolizing enzyme CYP2A5 in mouse primary hepatocytes. Toxicol. Appl. Pharmacol. 232, 135-141.
6. Arpiainen, S., Lämsä, V., Pelkonen, O., Yim, S. H., Gonzalez, F. J., and Hakkola, J. (2007). Aryl hydrocarbon receptor nuclear translocator and upstream stimulatory factor regulate cytochrome P450 2a5 transcription through a common E-box site. J. Mol. Biol. 369, 640-652.
7. Arpiainen, S., Raffalli-Mathieu, F., Lang, M. A., Pelkonen, O., and Hakkola, J. (2005). Regulation of the Cyp2a5 gene involves an aryl hydrocarbon receptor-dependent pathway. Mol. Pharmacol. 67, 1325-1333.
8. Benowitz, N. L., Swan, G. E., Jacob, P., Lessov-Schlaggar, C. N., and Tyndale, R. F. (2006). CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin. Pharmacol. Ther. 80, 457-467.
9. Cai, Y., Konishi, T., Han, G., Campwala, K. H., French, S. W., and Wan, Y. J. Y. (2002). The role of hepatocyte RXR alpha in xenobiotic-sensing nuclear receptor-mediated pathways. Eur. J. Pharm. Sci. 15, 89-96.
10. Cederbaum, A. I. (1991). Microsomal generation of reactive oxygen species and their possible role in alcohol hepatotoxicity. Alcohol Alcohol.Suppl. 1, 291-296.
11. Cederbaum, A. I., and Cohen, G. (1984). Microsomal oxidant radical production and ethanol oxidation. Methods Enzymol. 105, 516-522.
12. Cederbaum, A. I., Lu, Y., and Wu, D. (2009). Role of oxidative stress in alcohol-induced liver injury. Arch. Toxicol. 83, 519-548.
13. Cheung, C., Yu, A. M., Ward, J. M., Krausz, K. W., Akiyama, T. E., Feigenbaum, L., and Gonzalez, F. J. (2005). The CYP2E1-humanized transgenic mouse: Role of CYP2E1 in acetaminophen hepatotoxicity. Drug Metab. Disp. 33, 449-457.
14. De-Oliveira, A. C., Da-Matta, A. C., and Paumgartten, F. J. (2006). Plasmodium Berghei: Infection induces CYP2A5 and 2E1 while depressing other CYP isoforms in the mouse liver. Exp. Parasitol. 113, 256-261.
15. Enomoto, A., Itoh, K., Nagayoshi, E., Haruta, J., Kimura, T., O'Connor, T., Harada, T., and Yamamoto, M. (2001). High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol. Sci. 59, 169-177.
16. Gerjevic, L. N., Lu, S., Chaky, J. P., and Harrison-Findik, D. D. (2011). Regulation of heme oxygenase expression by alcohol, hypoxia and oxidative stress. World J. Biol. Chem. 2, 252-260.
17. Gilmore, W. J., and Kirby, G. M. (2004). Endoplasmic reticulum stress due to altered cellular redox status positively regulates murine hepatic CYP2A5 expression. J. Pharmacol. Exp. Ther. 308, 600-608.
18. Gong, P., and Cederbaum, A. I. (2006). Nrf2 is increased by CYP2E1 in rodent liver and HepG2 cells and protects against oxidative stress caused by CYP2E1. Hepatology 43, 144-153.
19. Jounaidi, Y., Bonfils, C., Perin, F., Negishi, M., and Lange, R. (1994). Overexpression of a cytochrome P450 of the 2a family (CYP2a5) in chemically induced hepatomas from female mice. Eur. J. Biochem. 219, 791-798.
20. Kobliakov, V., Kulikova, L., Samoilov, D., and Lang, M. A. (1993). High expression of cytochrome P4502a5 (coumarin 7-hydroxylase) in mouse hepatomas. Mol. Carcinog. 7, 276-280.
21. Koop, D. R., and Tierney, D. J. (1990). Multiple mechanisms in the regulation of ethanol-inducible cytochrome P450IIE1. Bioessays 12, 429-435.
22. Lamlé, J., Marhenke, S., Borlak, J., von Wasielewski, R., Eriksson, C. J., Geffers, R., Manns, M. P., Yamamoto, M., and Vogel, A. (2008). Nuclear factoreythroid 2-related factor 2 prevents alcohol-induced fulminant liver injury. Gastroenterology 134, 1159-1168.
23. Lamsa, V., Levonen, A. L., Leinonen, H., Yla-Herttuala, S., Yamamoto, M., and Hakkola, J. (2010). Cytochrome P4502A5 constitutive expression and induction by heavy metals is dependent on redox-sensitive transcription factor Nrf2 in liver. Chem. Res. Toxicol. 23, 977-985.
24. Lee, S. S., Buter, J. T., Pineau, T., Fernandez-Salguero, P., and Gonzalez, F. J. (1996). Role of CYP2E1 in the hepatotoxicity of acetaminophen. J. Biol. Chem. 271, 12063-12067.
25. Lieber, C. S. (1997). Cytochrome P-4502E1: Its physiological and pathological role. Physiol. Rev. 77, 517-544.
26. Lieber, C. S., and DeCarli, L. M. (1972). The role of the hepatic microsomal ethanol oxidizing system (MEOS) for ethanol metabolism in vivo. J. Pharmacol. Exp. Ther. 181, 279-287.
27. Lu, Y., and Cederbaum, A. I. (2006a). Enhancement by pyrazole of lipopolysaccharide-induced liver injury in mice: Role of cytochrome P4502E1 and 2A5. Hepatology 44, 263-274.
28. Lu, Y., and Cederbaum, A. I. (2006b). Cisplatin-induced hepatotoxicity is enhanced by elevated expression of cytochrome P450 2E1. Toxicol. Sci. 89, 515-523.
29. Lu, Y., and Cederbaum, A. I. (2008). CYP2E1 and oxidative liver injury by alcohol. Free Rad. Biol. Med. 44, 723-738.
30. Lu, Y., Gong, P., and Cederbaum, A. I. (2008). Pyrazole induced oxidative liver injury independent of CYP2E1/2A5 induction due to Nrf2 deficiency. Toxicology 252, 9-16.
31. Lu, Y., Kawashima, A., Horii, I., and Zhong, L. (2004). Effects of BSO and L-cysteine on drug-induced cytotoxicity in primary cell cultures: Drug-, cell type-, and species-specific difference. Drug Chem. Toxicol. 27, 269-280.
32. Lu, Y., Wang, X., and Cederbaum, A. I. (2005). Lipopolysaccharide-induced liver injury in rats treated with the CYP2E1 inducer pyrazole. Am. J. Physiol. Gastrointest. Liver Physiol. 289, G308-G319.
33. Lu, Y., Wu, D., Wang, X., Ward, S. C., and Cederbaum, A. I. (2010). Chronic alcohol-induced liver injury and oxidant stress are decreased in cytochrome P4502E1 knockout mice and restored in humanized cytochrome P4502E1 knock-in mice. Free Radic. Biol. Med. 49, 1406-1416.
34. Lu, Y., Zhuge, J., Wu, D., and Cederbaum, A. I. (2011). Ethanol induction of CYP2A5: Permissive role for CYP2E1. Drug Metab. Dispos. 39, 330-336.
35. Lu, Y., Zhuge, J., Wang, X., Bai, J., and Cederbaum, A. I. (2008). Cytochrome P450 2E1 contributes to ethanol-induced fatty liver in mice. Hepatology 47, 1483-1494.
36. Mäenpää, J., Sigusch, H., Raunio, H., Syngelmä, T., Vuorela, P., and Pelkonen, O. (1993). Differential inhibition of coumarin 7-hydroxylase activity in mouse and human liver microsomes. Biochem. Pharmacol. 45, 1035-1042.
37. Martín-Montalvo, A., Villalba, J. M., Navas, P., and de Cabo, R. (2011). NRF2, cancer and calorie restriction. Oncogene 30, 505-520.
38. Miyazaki, M., Yamazaki, H., Takeuchi, H., Saoo, K., Yokohira, M., Masumura, K., Nohmi, T., Funae, Y., Imaida, K., and Kamataki, T. (2005). Mechanisms of chemopreventive effects of 8-methoxypsoralen against 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung adenomas. Carcinogenesis 26, 1947-1955.
39. Niemela, O., Parkkila, S., Juvonen, R. O., Viitala, K., Gelboin, H. V., and Passanen, M. (2000). Cytochromes P4502A6, 2E1 and 3A and production of protein aldehyde adducts in the liver of patients with alcoholic and non-alcoholic liver diseases. J. Hepatol. 33, 893-901.
40. Siu, E. C., Wildenauer, D. B., and Tyndale, R. F. (2006). Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5. Psychopharmacology (Berl). 184, 401-408.
41. Slocum, S. L., and Kensler, T. W. (2011). Nrf2: Control of sensitivity to carcinogens. Arch. Toxicol. 85, 273-284.
42. Su, T., and Ding, X. (2004). Regulation of the cytochrome P4502A genes. Toxicol. Appl. Pharmacol. 199, 285-294.
43. Su, T., Zhang, Q., Swiatek, P., and Ding, X. (2002). Expression of the rat CYP2A3 gene in transgenic mice. Drug Metab. Dispos. 30, 548-552.
44. Wall, T. L., Schoedel, K., Ring, H. Z., Luczak, S. E., Katsuyoshi, D. M., and Tyndale, R. F. (2007). Differences in pharmacogenetics of nicotine and alcohol metabolism: Review and recommendations for future research. Nicotine Tobacco Res. 9(Suppl. 3), S459-S474.
45. Yokota, S., Higashi, E., Fukami, T., Yokoi, T., and Nakajima, M. (2011). Human CYP2A6 is regulated by nuclear factor-erythroid 2 related factor 2. Biochem. Pharmacol. 81, 289-294.
46. Zhou, X., Zhuo, X., Xie, F., Kluetzman, K., Shu, Y. Z., Humphreys, W. G., and Ding, X. (2010). Role of CYP2A5 in the clearance of nicotine and cotinine: Insights from studies on a CYP2a5-null mouse model. J. Pharmacol. Exp. Ther. 332, 578-587.